800-641-5880

Sign Up / Login     Free Shipping $99+

Discovering ECM9™

The Scientific Breakthrough that Inspired the Foundation of Keprea

Scientists From A World-Renown Laboratory Were The First To Discover And Patent The Anti-Inflammatory Properties Of A Unique Botanical Ingredient That Is Our Exclusive Revolutionary Ingredient, “ ECM9™”.

The botanical source of this ingredient had never been studied prior to 2010. Research into this new ingredient scientifically proved that it significantly and potently reduced collagen and elastin degradation and potently inhibited the production of several inflammatory markers while promoting collagen production. Importantly, ECM9™ significantly inhibited the genetic expression and activation of matrix metalloproteinease-9 (MMP9), one of the most potent inflammatory mediators of collagen and elastin breakdown.

How ECM9™ Works

It is well established that as the skin ages, less collagen is produced and low levels of ongoing chronic inflammation further damage the skin by breaking down collagen and elastin fibers. ECM9™ works to inhibit “ MMPs” which are responsible for breaking down collagen and elastin fibers. One of the most important MMPs for skin aging is MMP9. Keprea’s proprietary botanical ingredient, ECM9™, potently inhibits MMP9 at the cellular level by blocking gene expression and enzyme activity.

By blocking MMP9, ECM9™ works to protect and enhance skin collagen and elastin along with promoting collagen synthesis. Therefore, ECM9™ is uniquely positioned to be one of nature’s new highly potent anti-aging ingredients.

keprea ecm9
clinical-trial-results3

TESTED & PROVEN:
The Clinical Trial of ECM9™

Based on the strong preclinical data, a clinical trial was conducted with 78 women to clinically test the efficacy of ECM9™ as a powerful anti-aging ingredient.

Clinical Trial Design
Keprea worked with a well-respected dermatologist and a clinical testing facility to conduct a clinical trial to test the safety and efficacy of ECM9™ as a new proprietary anti-aging ingredient. The clinical trial was designed as an 8-week double-blind placebo-controlled trial in which our ECM9™ formulated face cream or a base formulation without ECM9™ was used twice a day in 78 women ranging from 35-65 years old. Evaluations were done at baseline, week 2, 4 and 8 to evaluate improvements in the skin. The objective of the trial was to determine if the following key signs of aging improved with the use of the ECM9™ ingredient:

Objective Measurements

  • Skin Texture
    0%
  • Fine Lines/Wrinkles
    0%
  • Firmness/Elasticity
    0%
  • Skin Clarity
    0%
  • Radiance/Luminosity
    0%
  • Skin Moisture
    0%

Consumer Evaluations

  • Skin Texture
    0%
  • Fine Lines/Wrinkles
    0%
  • Firmness/Elasticity
    0%
  • Skin Clarity
    0%
  • Radiance/Luminosity
    0%
  • Skin Moisture
    0%

Experience Pure Wellness